A case of topiramate-induced epistaxis.
The current case describes epistaxis in a patient treated with a daily regimen of topiramate 100mg for migraine. The patient had not a past medical history of nosebleeds and laboratory parameters were within normal ranges. She was then advised to withdraw topiramate, and the epistaxis resolved within 12 hours after its discontinuation. Since then, the patient never complained other blood clotting disorders. The potential antiplatelet activity of topiramate is discussed.
Polimeni
Giovanni
G
Istituto di Ricovero e Cura a Carattere Scientifico Centro Neurolesi Bonino-Pulejo, S.S. 113, Via Palermo, C.da Casazza, 98124, Messina - Italy. gpolimeni@unime.it
Grugno
Rosario
R
Vitetta
Antongiulio
A
Cordici
Francesco
F
Alagna
Antonella
A
Caputi
Achille P
AP
Bramanti
Placido
P
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects; D004844:Epistaxis / Q000097:blood / Q000139:chemically induced*; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D020326:Migraine without Aura / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077236:Topiramate
D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose